Min Huang

List of Publications by Year
in descending order

62 papers	3,458 citations	159585 30 h-index	144013 57 g-index
66 all docs	66 docs citations	66 times ranked	6246 citing authors

#	Article	IF	Citations
1	Discovery of Novel Pyrrolo[2,3-‹i›d‹/i›]pyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors. Journal of Medicinal Chemistry, 2022, 65, 1243-1264.	6.4	42
2	Evodiamine-Inspired Topoisomerase-Histone Deacetylase Dual Inhibitors: Novel Orally Active Antitumor Agents for Leukemia Therapy. Journal of Medicinal Chemistry, 2022, 65, 4818-4831.	6.4	15
3	Micropeptide PACMP inhibition elicits synthetic lethal effects by decreasing CtIP and poly(ADP-ribosyl)ation. Molecular Cell, 2022, 82, 1297-1312.e8.	9.7	24
4	Discovery of PHGDH inhibitors by virtual screening and preliminary structureâ€“activity relationship study. Bioorganic Chemistry, 2022, 121, 105705.	4.1	3
5	NAMPT-targeting PROTAC promotes antitumor immunity via suppressing myeloid-derived suppressor cell expansion. Acta Pharmaceutica Sinica B, 2022, 12, 2859-2868.	12.0	31
6	SLC1A1-mediated cellular and mitochondrial influx of R-2-hydroxyglutarate in vascular endothelial cells promotes tumor angiogenesis in IDH1-mutant solid tumors. Cell Research, 2022, 32, 638-658.	12.0	19
7	Natural Products in Cancer Therapy: Past, Present and Future. Natural Products and Bioprospecting, 2021, 11, 5-13.	4.3	237
8	Rational drug design of benzothiazole-based derivatives as potent signal transducer and activator of transcription 3 (STAT3) signaling pathway inhibitors. European Journal of Medicinal Chemistry, 2021, 216, 113333.	5.5	16
9	Harnessing Genomic Stress for Antitumor Immunity. Antioxidants and Redox Signaling, 2021, 34, 1128-1150.	5.4	5
10	A proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies. Molecular Cell, 2021, 81, 4076-4090.e8.	9.7	31
11	A Novel Allosteric Inhibitor of Phosphoglycerate Mutase 1 Suppresses Growth and Metastasis of Non-Small-Cell Lung Cancer. Cell Metabolism, 2019, 30, 1107-1119.e8.	16.2	52
12	Identification of metabolic vulnerabilities of receptor tyrosine kinases-driven cancer. Nature Communications, 2019, 10, 2701.	12.8	82
13	Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies. Journal of Medicinal Chemistry, 2019, 62, 3898-3923.	6.4	60
14	Fragment-based drug discovery of triazole inhibitors to block PDEÎ´-RAS protein-protein interaction. European Journal of Medicinal Chemistry, 2019, 163, 597-609.	5.5	20
15	Design, synthesis and biological evaluation of tetrahydronaphthyridine derivatives as bioavailable CDK4/6 inhibitors for cancer therapy. European Journal of Medicinal Chemistry, 2018, 148, 140-153.	5.5	12
16	RNA-splicing factor SART3 regulates translesion DNA synthesis. Nucleic Acids Research, 2018, 46, 4560-4574.	14.5	23
17	Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy. Acta Pharmaceutica Sinica B, 2018, 8, 552-562.	12.0	294
18	Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors. Cell, 2018, 175, 186-199.e19.	28.9	166

#	Article	IF	Citations
19	c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors. Clinical Cancer Research, 2017, 23, 974-984.	7.0	27
20	Polymeric immunoglobulin receptor promotes tumor growth in hepatocellular carcinoma. Hepatology, 2017, 65, 1948-1962.	7.3	43
21	Phosphoglycerate mutase 1 regulates dNTP pool and promotes homologous recombination repair in cancer cells. Journal of Cell Biology, 2017, 216, 409-424.	5.2	52
22	Development of the First Generation of Disulfide-Based Subtype-Selective and Potent Covalent Pyruvate Dehydrogenase Kinase 1 (PDK1) Inhibitors. Journal of Medicinal Chemistry, 2017, 60, 2227-2244.	6.4	55
23	Chemotherapy-induced intestinal inflammatory responses are mediated by exosome secretion of double-strand DNA via AIM2 inflammasome activation. Cell Research, 2017, 27, 784-800.	12.0	149
24	Ataxin-3 promotes genome integrity by stabilizing Chk1. Nucleic Acids Research, 2017, 45, 4532-4549.	14.5	40
25	Exploiting histone deacetylases for cancer therapy: from hematological malignancies to solid tumors. Science China Life Sciences, 2017, 60, 94-97.	4.9	14
26	6â€Methoxyethylaminoâ€numonafide inhibits hepatocellular carcinoma xenograft growth as a single agent and in combination with sorafenib. FASEB Journal, 2017, 31, 5453-5465.	0.5	9
27	Polî· O-GlcNAcylation governs genome integrity during translesion DNA synthesis. Nature Communications, 2017, 8, 1941.	12.8	34
28	Aspirin Inhibits Cancer Metastasis and Angiogenesis via Targeting Heparanase. Clinical Cancer Research, 2017, 23, 6267-6278.	7.0	94
29	Aspirin disrupts the mTOR-Raptor complex and potentiates the anti-cancer activities of sorafenib via mTORC1 inhibition. Cancer Letters, 2017, 406, 105-115.	7.2	32
30	RBM45 competes with HDAC1 for binding to FUS in response to DNA damage. Nucleic Acids Research, 2017, 45, 12862-12876.	14.5	25
31	Identification of Epigallocatechin-3- Gallate as an Inhibitor of Phosphoglycerate Mutase 1. Frontiers in Pharmacology, 2017, 8, 325.	3.5	45
32	Phosphoglycerate Mutase 1 Predicts the Poor Prognosis of Oral Squamous Cell Carcinoma and is Associated with Cell Migration. Journal of Cancer, 2017, 8, 1943-1951.	2.5	31
33	Parkin regulates translesion DNA synthesis in response to UV radiation. Oncotarget, 2017, 8, 36423-36437.	1.8	8
34	Discovery and structure activity relationship study of novel indazole amide inhibitors for extracellular signal-regulated kinase1/2 (ERK1/2). Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2600-2604.	2.2	11
35	Feedback Activation of Leukemia Inhibitory Factor Receptor Limits Response to Histone Deacetylase Inhibitors in Breast Cancer. Cancer Cell, 2016, 30, 459-473.	16.8	117
36	One-pot N-glycosylation remodeling of IgG with non-natural sialylglycopeptides enables glycosite-specific and dual-payload antibodyâ€“drug conjugates. Organic and Biomolecular Chemistry, 2016, 14, 9501-9518.	2.8	88

#	Article	IF	Citations
37	REV1 promotes PCNA monoubiquitination through interacting with ubiquitinated RAD18. Journal of Cell Science, 2016, 129, 1223-33.	2.0	24
38	iTRAQ-based chromatin proteomic screen reveals CHD4-dependent recruitment of MBD2 to sites of DNA damage. Biochemical and Biophysical Research Communications, 2016, 471, 142-148.	2.1	7
39	Design and discovery of new pyrimidine coupled nitrogen aromatic rings as chelating groups of JMJD3 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 721-725.	2.2	17
40	The role of stearoyl-coenzyme A desaturase 1 in clear cell renal cell carcinoma. Tumor Biology, 2016, 37, 479-489.	1.8	12
41	The Machadoâ€“Joseph Disease Deubiquitinase Ataxin-3 Regulates the Stability and Apoptotic Function of p53. PLoS Biology, 2016, 14, e2000733.	5.6	66
42	DCLAK11, a multi-tyrosine kinase inhibitor, exhibits potent antitumor and antiangiogenic activity in vitro. Acta Pharmacologica Sinica, 2015, 36, 1266-1276.	6.1	3
43	FANCD2 and REV1 cooperate in the protection of nascent DNA strands in response to replication stress. Nucleic Acids Research, 2015, 43, 8325-8339.	14.5	38
44	c-Myc Alterations Confer Therapeutic Response and Acquired Resistance to c-Met Inhibitors in MET-Addicted Cancers. Cancer Research, 2015, 75, 4548-4559.	0.9	47
45	JX06 Selectively Inhibits Pyruvate Dehydrogenase Kinase PDK1 by a Covalent Cysteine Modification. Cancer Research, 2015, 75, 4923-4936.	0.9	61
46	Lactate Dehydrogenase B Is Associated with the Response to Neoadjuvant Chemotherapy in Oral Squamous Cell Carcinoma. PLoS ONE, 2015, 10, e0125976.	2.5	30
47	Acetylation at lysine 71 inactivates superoxide dismutase 1 and sensitizes cancer cells to genotoxic agents. Oncotarget, 2015, 6, 20578-20591.	1.8	20
48	Yhhu3813 is a novel selective inhibitor of c-Met Kinase that inhibits c-Met-dependent neoplastic phenotypes of human cancer cells. Acta Pharmacologica Sinica, 2014, 35, 89-97.	6.1	15
49	SOMG-833, a Novel Selective c-MET Inhibitor, Blocks c-METâ€“Dependent Neoplastic Effects and Exerts Antitumor Activity. Journal of Pharmacology and Experimental Therapeutics, 2014, 350, 36-45.	2.5	6
50	Molecularly targeted cancer therapy: some lessons from the past decade. Trends in Pharmacological Sciences, 2014, 35, 41-50.	8.7	255
51	Discovery and Optimization of 4,5-Diarylisoxazoles as Potent Dual Inhibitors of Pyruvate Dehydrogenase Kinase and Heat Shock Protein 90. Journal of Medicinal Chemistry, 2014, 57, 9832-9843.	6.4	34
52	Discovery of potent N-(isoxazol-5-yl)amides as HSP90 inhibitors. European Journal of Medicinal Chemistry, 2014, 87, 765-781.	5.5	33
53	SOMCL-863, a novel, selective and orally bioavailable small-molecule c-Met inhibitor, exhibits antitumor activity both in vitro and in vivo. Cancer Letters, 2014, 351, 143-150.	7.2	13
54	Mismatch repair protein MSH2 regulates translesion DNA synthesis following exposure of cells to UV radiation. Nucleic Acids Research, 2013, 41, 10312-10322.	14.5	25

#	Article	IF	Citations
55	Small-Molecule Inhibitors of USP1 Target ID1 Degradation in Leukemic Cells. Molecular Cancer Therapeutics, 2013, 12, 2651-2662.	4.1	137
56	Inhibition of the Nedd8 System Sensitizes Cells to DNA Interstrand Cross-linking Agents. Molecular Cancer Research, 2012, 10, 369-377.	3.4	61
57	Human MutS and FANCM complexes function as redundant DNA damage sensors in the Fanconi Anemia pathway. DNA Repair, 2011, 10, 1203-1212.	2.8	26
58	A new nuclease member of the FAN club. Nature Structural and Molecular Biology, 2010, 17, 926-928.	8.2	35
59	The FANCM/FAAP24 Complex Is Required for the DNA Interstrand Crosslink-Induced Checkpoint Response. Molecular Cell, 2010, 39, 259-268.	9.7	114
60	Inactivation of Murine Usp1 Results in Genomic Instability and a Fanconi Anemia Phenotype. Developmental Cell, 2009, 16, 314-320.	7.0	217
61	Chk1 and Chk2 are differentially involved in homologous recombination repair and cell cycle arrest in response to DNA double-strand breaks induced by camptothecins. Molecular Cancer Therapeutics, 2008, 7, 1440-1449.	4.1	64
62	Chimmitecan, a Novel 9-Substituted Camptothecin, with Improved Anticancer Pharmacologic Profiles In vitro and In vivo. Clinical Cancer Research, 2007, 13, 1298-1307.	7.0	91